Like what you've read?

On Line Opinion is the only Australian site where you get all sides of the story. We don't
charge, but we need your support. Here�s how you can help.

  • Advertise

    We have a monthly audience of 70,000 and advertising packages from $200 a month.

  • Volunteer

    We always need commissioning editors and sub-editors.

  • Contribute

    Got something to say? Submit an essay.


 The National Forum   Donate   Your Account   On Line Opinion   Forum   Blogs   Polling   About   
On Line Opinion logo ON LINE OPINION - Australia's e-journal of social and political debate

Subscribe!
Subscribe





On Line Opinion is a not-for-profit publication and relies on the generosity of its sponsors, editors and contributors. If you would like to help, contact us.
___________

Syndicate
RSS/XML


RSS 2.0

Curing Ebola with Thomas Pogge

By Jed Lea-Henry - posted Friday, 21 November 2014


Fundamentally, the Health Impact Fund rewards pharmaceutical innovation according to the successful outcomes of the new medicine, rather than according to whether or not the new medicine has a sufficiently wealthy target audience.

Though not cheap to implement, when divested across multiple state actors, and when considering the Fund's ability to provide future cost savings by mitigating against humanitarian crises, the Fund would not be restrictively expensive - potentially even cost-neutral.

Pogge's initiative represents a significant improvement upon the alternative of governments individually selecting under-researched diseases and attracting scientists by competing with private sector salaries. Such 'push' factor incentives are notoriously ineffective, especially when compared to the 'pull' factor incentives provided by the possibility of exponentially large back-end profits. As opposed to direct government funding, the Health Impact Fund maintains an inducement for private enterprise participation.

Advertisement

By delivering a viable alternative to the patent system, the Health Impact Fund offers an otherwise absent encouragement for socially conscious companies to develop drugs targeted toward global health challenges such as Ebola. What's more, pharmaceutical companies would likely be further tempted to participate in the Fund by the prospect that they would receive a public relations benefit above and beyond their profit margins.

Large-scale global institutional reform is near impossible to achieve. It is here that Thomas Pogge's project gains increased credibility. Rather than a sweeping reform, the Health Impact Fund is a relatively small, non-intrusive supplement to the existing institutional order - yet intelligently targeted in such a way as to have the capacity to produce disproportionately large global health outcomes.

As a means to ensure that private companies continue to invest in pharmaceutical development, there is simply no conceivable alternative to the patent system. It is therefore vital that the harmful side-effects of the system, such as under-investment in diseases that prominently affect poorer populations are offset as much as possible by supplementary design features. Thomas Pogge's Health Impact Fund is the best available means of achieving this. The best chance of ensuring that research and developed is targeted towards the diseases and regions where it can have the greatest health impact. And the best means of mitigating against future global health crises on the scale of the current Ebola outbreak.

  1. Pages:
  2. 1
  3. Page 2
  4. All


Discuss in our Forums

See what other readers are saying about this article!

Click here to read & post comments.

5 posts so far.

Share this:
reddit this reddit thisbookmark with del.icio.us Del.icio.usdigg thisseed newsvineSeed NewsvineStumbleUpon StumbleUponsubmit to propellerkwoff it

About the Author

Jed Lea-Henry is a writer, academic, and the host of the Korea Now Podcast. You can follow Jed's work, or contact him directly at Jed Lea-Henry and on Twitter @JedLeaHenry.

Other articles by this Author

All articles by Jed Lea-Henry

Creative Commons LicenseThis work is licensed under a Creative Commons License.

Article Tools
Comment 5 comments
Print Printable version
Subscribe Subscribe
Email Email a friend
Advertisement

About Us Search Discuss Feedback Legals Privacy